A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non-Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body Radiotherapy

Mark A. Henderson, David J. Hoopes, James Fletcher, Pei Fen Lin, Mark Tann, Constantin Yiannoutsos, Mark D. Williams, Achilles J. Fakiris, Ronald C. McGarry, Robert D. Timmerman

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: Routine assessment was made of tumor metabolic activity as measured by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in Stage I non-small-cell lung cancer (NSCLC). This report describes PET correlates prospectively collected after stereotactic body radiotherapy (SBRT) for patients with medically inoperable NSCLC. Methods and Materials: 14 consecutive patients with medically inoperable Stage I NSCLC were enrolled. All patients received SBRT to 60-66 Gy in three fractions. Patients underwent serial planned FDG-PET/computed tomography fusion imaging before SBRT and at 2, 26, and 52 weeks after SBRT. Results: With median follow-up of 30.2 months, no patients experienced local failure. One patient developed regional failure, 1 developed distant failure, and 1 developed a second primary. The median tumor maximum standardized uptake value (SUVmax) before SBRT was 8.70. The median SUVmax values at 2, 26, and 52 weeks after SBRT were 6.04, 2.80, and 3.58, respectively. Patients with low pre-SBRT SUV were more likely to experience initial 2-week rises in SUV, whereas patients with high pre-SBRT SUV commonly had SUV declines 2 weeks after treatment (p = 0.036). Six of 13 patients had primary tumor SUVmax >3.5 at 12 months after SBRT but remained without evidence of local disease failure on further follow-up. Conclusions: A substantial proportion of patients may have moderately elevated FDG-PET SUVmax at 12 months without evidence of local failure on further follow-up. Thus, slightly elevated PET SUVmax should not be considered a surrogate for local treatment failure. Our data do not support routine serial FDG-PET/computed tomography for follow-up of patients receiving SBRT for Stage I NSCLC.

Original languageEnglish
Pages (from-to)789-795
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume76
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Radiosurgery
Fluorodeoxyglucose F18
Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
lungs
radiation therapy
positrons
tomography
cancer
tumors
Neoplasms
Treatment Failure
proportion
fusion

Keywords

  • 18F-fluorodeoxyglucose positron emission tomography
  • Body radiosurgery
  • Lung cancer
  • Non-small-cell lung cancer
  • Stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non-Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body Radiotherapy. / Henderson, Mark A.; Hoopes, David J.; Fletcher, James; Lin, Pei Fen; Tann, Mark; Yiannoutsos, Constantin; Williams, Mark D.; Fakiris, Achilles J.; McGarry, Ronald C.; Timmerman, Robert D.

In: International Journal of Radiation Oncology Biology Physics, Vol. 76, No. 3, 01.03.2010, p. 789-795.

Research output: Contribution to journalArticle

@article{ef956945938a47378e9b5bacb8a2e41b,
title = "A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non-Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body Radiotherapy",
abstract = "Purpose: Routine assessment was made of tumor metabolic activity as measured by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in Stage I non-small-cell lung cancer (NSCLC). This report describes PET correlates prospectively collected after stereotactic body radiotherapy (SBRT) for patients with medically inoperable NSCLC. Methods and Materials: 14 consecutive patients with medically inoperable Stage I NSCLC were enrolled. All patients received SBRT to 60-66 Gy in three fractions. Patients underwent serial planned FDG-PET/computed tomography fusion imaging before SBRT and at 2, 26, and 52 weeks after SBRT. Results: With median follow-up of 30.2 months, no patients experienced local failure. One patient developed regional failure, 1 developed distant failure, and 1 developed a second primary. The median tumor maximum standardized uptake value (SUVmax) before SBRT was 8.70. The median SUVmax values at 2, 26, and 52 weeks after SBRT were 6.04, 2.80, and 3.58, respectively. Patients with low pre-SBRT SUV were more likely to experience initial 2-week rises in SUV, whereas patients with high pre-SBRT SUV commonly had SUV declines 2 weeks after treatment (p = 0.036). Six of 13 patients had primary tumor SUVmax >3.5 at 12 months after SBRT but remained without evidence of local disease failure on further follow-up. Conclusions: A substantial proportion of patients may have moderately elevated FDG-PET SUVmax at 12 months without evidence of local failure on further follow-up. Thus, slightly elevated PET SUVmax should not be considered a surrogate for local treatment failure. Our data do not support routine serial FDG-PET/computed tomography for follow-up of patients receiving SBRT for Stage I NSCLC.",
keywords = "18F-fluorodeoxyglucose positron emission tomography, Body radiosurgery, Lung cancer, Non-small-cell lung cancer, Stereotactic body radiation therapy",
author = "Henderson, {Mark A.} and Hoopes, {David J.} and James Fletcher and Lin, {Pei Fen} and Mark Tann and Constantin Yiannoutsos and Williams, {Mark D.} and Fakiris, {Achilles J.} and McGarry, {Ronald C.} and Timmerman, {Robert D.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.ijrobp.2009.02.051",
language = "English",
volume = "76",
pages = "789--795",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non-Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body Radiotherapy

AU - Henderson, Mark A.

AU - Hoopes, David J.

AU - Fletcher, James

AU - Lin, Pei Fen

AU - Tann, Mark

AU - Yiannoutsos, Constantin

AU - Williams, Mark D.

AU - Fakiris, Achilles J.

AU - McGarry, Ronald C.

AU - Timmerman, Robert D.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Purpose: Routine assessment was made of tumor metabolic activity as measured by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in Stage I non-small-cell lung cancer (NSCLC). This report describes PET correlates prospectively collected after stereotactic body radiotherapy (SBRT) for patients with medically inoperable NSCLC. Methods and Materials: 14 consecutive patients with medically inoperable Stage I NSCLC were enrolled. All patients received SBRT to 60-66 Gy in three fractions. Patients underwent serial planned FDG-PET/computed tomography fusion imaging before SBRT and at 2, 26, and 52 weeks after SBRT. Results: With median follow-up of 30.2 months, no patients experienced local failure. One patient developed regional failure, 1 developed distant failure, and 1 developed a second primary. The median tumor maximum standardized uptake value (SUVmax) before SBRT was 8.70. The median SUVmax values at 2, 26, and 52 weeks after SBRT were 6.04, 2.80, and 3.58, respectively. Patients with low pre-SBRT SUV were more likely to experience initial 2-week rises in SUV, whereas patients with high pre-SBRT SUV commonly had SUV declines 2 weeks after treatment (p = 0.036). Six of 13 patients had primary tumor SUVmax >3.5 at 12 months after SBRT but remained without evidence of local disease failure on further follow-up. Conclusions: A substantial proportion of patients may have moderately elevated FDG-PET SUVmax at 12 months without evidence of local failure on further follow-up. Thus, slightly elevated PET SUVmax should not be considered a surrogate for local treatment failure. Our data do not support routine serial FDG-PET/computed tomography for follow-up of patients receiving SBRT for Stage I NSCLC.

AB - Purpose: Routine assessment was made of tumor metabolic activity as measured by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in Stage I non-small-cell lung cancer (NSCLC). This report describes PET correlates prospectively collected after stereotactic body radiotherapy (SBRT) for patients with medically inoperable NSCLC. Methods and Materials: 14 consecutive patients with medically inoperable Stage I NSCLC were enrolled. All patients received SBRT to 60-66 Gy in three fractions. Patients underwent serial planned FDG-PET/computed tomography fusion imaging before SBRT and at 2, 26, and 52 weeks after SBRT. Results: With median follow-up of 30.2 months, no patients experienced local failure. One patient developed regional failure, 1 developed distant failure, and 1 developed a second primary. The median tumor maximum standardized uptake value (SUVmax) before SBRT was 8.70. The median SUVmax values at 2, 26, and 52 weeks after SBRT were 6.04, 2.80, and 3.58, respectively. Patients with low pre-SBRT SUV were more likely to experience initial 2-week rises in SUV, whereas patients with high pre-SBRT SUV commonly had SUV declines 2 weeks after treatment (p = 0.036). Six of 13 patients had primary tumor SUVmax >3.5 at 12 months after SBRT but remained without evidence of local disease failure on further follow-up. Conclusions: A substantial proportion of patients may have moderately elevated FDG-PET SUVmax at 12 months without evidence of local failure on further follow-up. Thus, slightly elevated PET SUVmax should not be considered a surrogate for local treatment failure. Our data do not support routine serial FDG-PET/computed tomography for follow-up of patients receiving SBRT for Stage I NSCLC.

KW - 18F-fluorodeoxyglucose positron emission tomography

KW - Body radiosurgery

KW - Lung cancer

KW - Non-small-cell lung cancer

KW - Stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=76049108779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049108779&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.02.051

DO - 10.1016/j.ijrobp.2009.02.051

M3 - Article

C2 - 19473777

AN - SCOPUS:76049108779

VL - 76

SP - 789

EP - 795

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -